Estimating risks of de novo kidney diseases after living kidney donation

American Journal of Transplantation

Volumn 14, Issue 3, 2014, Pages 538-544

  Steiner, R W ^a   Ix, J H ^a,b,c   Rifkin, D E ^a,b,c   Gert, B ^d,e,f  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DARTMOUTH COLLEGE   (United States)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Donor outcomes; donor risk; donor screening

Indexed keywords

ARTICLE; DE NOVO KIDNEY DISEASE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HUMAN; KIDNEY DISEASE; KIDNEY DONOR; LIVING DONOR; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; GLOMERULAR FILTRATION RATE; HUMANS; INFANT; INFANT, NEWBORN; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MIDDLE AGED; NEPHRECTOMY; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TISSUE AND ORGAN HARVESTING; YOUNG ADULT;

EID: 84896712352     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12625     Document Type: Article

References (30)

1. Mandelbrot DA, Pavlakis M., Living donor practices in the United States. Adv Chronic Kidney Dis 2012; 19: 212-219.
2. Ramos E, Vijayan A, Vella J., 2013; Evaluation of the living kidney donor and risk of donor nephrectomy. In: Brennan DC, ed. Up To Date. Available at: http://www.uptodate.com. Accessed May 2, 2013.
3. Tong A, Chapman JR, Wong G, de Bruijn J, Craig JC., Screening and follow-up of living kidney donors: A systematic review of clinical practice guidelines. Transplantation 2011; 92: 962-972.
4. Steiner RW, Danovitch G., The medical evaluation and the risk of end stage renal disease for living kidney donors. In:, Steiner RW, ed. Educating, evaluating, and selecting living kidney donors, 1st ed. Dordrecht, the Netherlands: Kluwer Academic Publishers, 2004, pp. 51-79.
5. Kido R, Shibagaki Y, Iwadoh K, et al. How do living kidney donors develop end-stage renal disease ? Am J Transplant 2009; 9: 2514-2519.
6. Ibrahim HN, Foley R, Tan LP, et al. Long-term consequences of kidney donation. N Engl J Med 2009; 360: 449-460.
7. Hoerger TJ, Wittenborn JS, Segel JE, et al. A health policy model of CKD: 1. Model construction, assumptions, and validation of health consequences. Centers for Disease Control and Prevention CKD Initiative. Am J Kidney Dis 2010; 55: 452-562.
8. Grams ME, Chow EK, Segev DL, Coresh J., Lifetime incidence of CKD stages 3-5 in the United States. Am J Kidney Dis 2013; 62: 245-252.
9. Steiner RW., ' Normal for Now' or 'At Future Risk': A double standard for selecting young and older living kidney donors. Am J Transplant 2010; 10: 1-5.
10. United States Renal Data System (USRDS). www.USRDS.org
11. Plantinga LC, Crews DC, Coresh J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol 2010; 5: 673-682.
12. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF., Lifetime risk for diabetes mellitus in the United States. JAMA 2003; 290: 1884-1890.
13. Ibrahim HN, Hostetter TH., Diabetic nephropathy. J Am Soc Nephrol 1997; 8: 487-493.
14. Ritz E, Orth SR., Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341: 1127-1133.
15. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J., Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011; 305: 2532-2539.
16. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
17. Schlessinger SD, Tankersley MR, Curtis JJ., Clinical documentation of end-stage renal disease due to hypertension. Am J Kid Dis 1994; 23: 655-660.
18. Hsu C., Does non-malignant hypertension cause renal insufficiency? Evidence-based perspective. Curr Opin Nephrol Hyperten 2011; 11: 267-272.
19. Roland AS, Hildreth EA, Sellers AM., Occult primary renal disease in the hypertensive patient. Arch Int Med 1964; 113: 101-110.
20. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Part 4. Definition and Classification of Stages of Chronic Kidney Disease. Guideline 1. Definition and Stages of Chronic Kidney Disease. Available at: http://www.kidney.org/professionals/KDOQI/guidelines-ckd/toc.htm. Accessed February 2012.
21. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR., Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009; 20: 1069-1077.
22. Keith DS, Nichols GA, Guillion CM, Brown JB, Smith DH., Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663.
23. Lentine KL, Schnitzler MA, Xiao H, et al. Racial variation in medical outcomes among living kidney donors. N Engl J Med 2010; 363: 724-732.
24. Boyarsky BJ, Van Arendonk K, Deshpande NA, James NT, Montgomery RA, Segev DL., Johns Hopkins WHOLE-DONOR Study. Race is associated with new onset hypertension and diabetes after living kidney donation. Abstract presented at American Transplant Congress, Boston, MA, June 6-12, 2012.
25. Cherikh WS, Young CJ, Kramer BF, Taranto SE, Randall HB, Fan PY., Ethnic and gender related differences in the risk of end stage renal disease after living kidney donation. Am J Transplant 2011; 11: 1650-1655.
26. Mjoen G, Hallan S, Hartmann A, et al. Long term risks for kidney donors. Kidney Int (online). Published November 27, 2013.
27. Cherikh W, Young C, Taranto S, Kramer B, Randall H, Fan PY., Prior living kidney donors subsequently placed on the waiting list: An Organ Procurement and Transplantation Network (OPTN) analysis. Presented at the Annual Meeting of American Society of Multicultural Health and Transplant Professionals (ASMHTP), September 25, 2009, Las Vegas, NV.
28. www.unos.org
29. Slinin Y, Ishani A, Rector T, et al. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: A systematic review for a KDOQI Clinical Practice Guideline. Am J Kidney Dis 2012; 60: 747-769.
30. Reese PP, Caplan AL, Kesselheim AS, Bloom RD., Creating a medical, ethical, and legal framework for complex living kidney donors. Clin J Am Soc Nephrol 2006; 1: 628-633.